Stockscreener 앱 받기
17.76
2.15%
-0.39
시간 외 거래:
17.76
Novocure Ltd 주식(NVCR)의 최신 뉴스
Ratio Analysis: Unpacking NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
A year in review: NovoCure Ltd (NVCR)’s performance in the last year - uspostnews.com
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance
NovoCure Ltd’s latest rating changes from various analysts - knoxdaily.com
What is NovoCure Ltd (NVCR) Stock Return on Shareholders’ Capital? - Sete News
Russell Investments Group Ltd. Sells 2,135 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure First Quarter 2025 Earnings: Beats Expectations - simplywall.st
H.C. Wainwright maintains Buy on NovoCure, $38 price target By Investing.com - Investing.com Canada
NovoCure Ltd [NVCR] Shares Jump Approximately 56.80% Over the Year - knoxdaily.com
Why NovoCure Stock Skyrocketed This Week - Yahoo Finance
H.C. Wainwright maintains Buy on NovoCure, $38 price target - Investing.com
NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript - Insider Monkey
NovoCure (NASDAQ:NVCR) Cut to “Sell” at StockNews.com - Defense World
NovoCure: Q1 Earnings Snapshot - Huron Daily Tribune
Bank of Montreal Can Buys New Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
Novocure’s Q1 2025: Revenue Growth and Strategic Advances - TipRanks
NovoCure Ltd. Earnings Call: Growth Amid Financial Challenges - TipRanks
NovoCure (NVCR) Stock Rises on Strong Quarterly Earnings - GuruFocus
Novocure (NVCR) Sees Early Revenue from Lung Cancer Treatments | NVCR Stock News - GuruFocus
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 - Benzinga
Novocure’s device for metastatic NSCLC treatment gains CE Mark - MSN
NovoCure (NVCR) Reports Strong Q1 Revenue Growth Amid Optune Lua Expansion - GuruFocus
Stocks of NovoCure Ltd (NVCR) are poised to climb above their peers - Sete News
NovoCure Surpasses Q1 Expectations - Mitrade
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
NovoCure Surpasses Q1 Expectations - The Motley Fool
NovoCure Ltd Reports Q1 2025 Earnings: EPS Loss of $0.31 Beats E - GuruFocus
Novocure Ltd earnings beat by $0.18, revenue topped estimates - Investing.com India
Novocure Reports First Quarter 2025 Financial Results | NVCR Sto - GuruFocus
Novocure (NVCR) Surpasses Q1 Revenue Projections, Reports $154.9 - GuruFocus
NovoCure Ltd Reports Q1 2025 Earnings: EPS Loss of $0.31 Beats Estimate, Revenue of $155 Million Exceeds Expectations - GuruFocus
Novocure Reports First Quarter 2025 Financial Results - TradingView
NovoCure Ltd SEC 10-Q Report - TradingView
Novocure to present Phase 3 PANOVA-3 trial results at ASCO 2025 - TipRanks
NovoCure's Earnings: A Preview - Benzinga
Novocure (NVCR) to Showcase Key PANOVA-3 Trial Findings at ASCO 2025 | NVCR Stock News - GuruFocus
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical T - GuruFocus
Novocure price target lowered to $34 from $42 at Piper Sandler - TipRanks
Novocure (NVCR) Faces Revised Price Target Amid Investor Opportu - GuruFocus
Novocure (NVCR) Faces Revised Price Target Amid Investor Opportunities | NVCR Stock News - GuruFocus
Novocure sees 6% spike from EU nod for electric lung cancer therapy gadget - Mugglehead Magazine
Novocure (NVCR) Gains CE Mark for Optune Lua in Lung Cancer Treatment | NVCR Stock News - GuruFocus
Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer | NVCR Stock News - GuruFocus
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer - Yahoo Finance
LPL Financial LLC Acquires Shares of 27,861 NovoCure Limited (NASDAQ:NVCR) - Defense World
Form DEFA14A NovoCure Ltd - StreetInsider
11.62%
0.20%
자본화:
|
볼륨(24시간):